Croda and AAHI enter vaccine adjuvant formulations partnership

2024-03-20

疫苗

Croda and AAHI enter vaccine adjuvant formulations partnership

Preview

来源: Pharmaceutical Technology

Croda and the AAHI aim to accelerate the development of new adjuvants and formulations. Credit: Momentum studio via Shutterstock.

Croda International has entered a collaboration agreement with the Access to Advanced Health Institute (AAHI) to innovate and develop vaccine adjuvant formulations.

Under this deal, the parties will use their combined capabilities to make new vaccine adjuvants accessible worldwide. This approach will aid in the advancement of next-generation vaccines that are robust and durable.

The AAHI has platform technologies designed to harness the immune system in fighting diseases.

In addition, the institute has an adjuvant formulation portfolio used in numerous vaccine candidates for fighting major infectious and neglected ailments identified by the World Health Organization (WHO) as global threats.

The exclusive agreement between the AAHI and Croda encompasses joint research and development efforts.

See Also:

Cancer Research UK and CRIS fund lung cancer vaccine research

Preview

来源: Pharmaceutical Technology

Zydus Lifesciences files patent for liquid oral formulation of sildenafil for various diseases

Preview

来源: Pharmaceutical Technology

By combining their expertise, the parties are set to accelerate the quick development of new adjuvants and formulations.

They also plan to establish efficient manufacturing processes for large-scale production to meet the demands of the vaccine industry and global health needs.

Under the partnership, Croda will gain specific rights for the marketing, distribution, and sale of selected new adjuvant formulations that are developed by the AAHI.

These formulations are intended for research purposes and clinical development.

Croda will become the AAHI’s exclusive authorised manufacturer in various countries to scale up manufacturing processes, providing support for Phase III trials and commercial usage.

Croda Life Sciences president Daniele Piergentili said: “This partnership marks another significant milestone in our endeavour to offer a comprehensive portfolio of adjuvants for the vaccines of tomorrow.

“It perfectly aligns with our pharmaceutical strategy to ‘Empower biologics delivery’ and underscores our commitment to making substantial contributions to the successful development and commercialisation of WHO-listed pipeline vaccines.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构